◀ Back to ABL1

ABL1 — AMN

Text-mined interactions from Literome

Weisberg et al., Cancer Cell 2005 (Leukemia, Myelogenous, Chronic, BCR-ABL Positive...) : Characterization of AMN107 , a selective inhibitor of native and mutant Bcr-Abl
Golemovic et al., Clin Cancer Res 2005 (Leukemia, Myelogenous, Chronic, BCR-ABL Positive) : AMN107 , a novel aminopyrimidine inhibitor of Bcr-Abl , has in vitro activity against imatinib-resistant chronic myeloid leukemia
Kantarjian et al., Ann Intern Med 2006 (Disease Progression...) : In light of the limitations of imatinib against these factors, newer tyrosine kinase inhibitors, including dasatinib ( a multitargeted kinase inhibitor of BCR-ABL and Src family kinases ) and nilotinib ( AMN107 , a selective BCR-ABL inhibitor ), may provide promising treatment options for patients with CML